Transcutaneous immunization of healthy volunteers with an attenuated Listeria monocytogenes vaccine strain and cholera toxin adjuvant

Vaccine

Volumn 31, Issue 32, 2013, Pages 3257-3261

  Eypper, Elizabeth H ^a   Johnson, Paul V ^a   Purro, Eva I ^b   Hohmann, Elizabeth L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b List Biological Laboratories Inc   (United States)

Author keywords

Attenuated vector; Clinical trial; ELISpot; Listeria monocytogenes; Transcutaneous; Vaccination

Indexed keywords

BACTERIAL VACCINE; CHOLERA TOXIN; GAMMA INTERFERON; LISTERIA MONOCYTOGENES VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ERUPTION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INNATE IMMUNITY; MALE; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ADULT; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CHOLERA TOXIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; LISTERIA MONOCYTOGENES; MALE; TRANSDERMAL PATCH; VACCINES, ATTENUATED;

EID: 84879464595     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.028     Document Type: Article

References (12)

1. Le D.T., Brockstedt D.G., Nir-Paz R., Hampl J., Mathur S., Nemunaitis J., et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 2012, 18:858-868.
2. Maciag P.C., Radulovic S., Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009, 27:3975-3983.
3. Angelakopoulos H., Loock K., Sisul D.M., Jensen E.R., Miller J.F., Hohmann E.L. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect Immun 2002, 70:3592-3601.
4. Johnson P.V., Blair B.M., Zeller S., Kotton C.N., Hohmann E.L. Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers. Microbiol Immunol 2011, 55:304-317.
5. Clark R.A. Skin-resident Tcells: the ups and downs of on site immunity. J Invest Dermatol 2010, 130:362-370.
6. Nelson K.S., Janssen J.M., Troy S.B., Maldonado Y. Intradermal fractional dose inactivated polio vaccine: a review of the literature. Vaccine 2012, 30:121-125.
7. Guerena-Burgueno F., Hall E.R., Taylor D.N., Cassels F.J., Scott D.A., Wolf M.K., et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 2002, 70:1874-1880.
8. Frech S.A., Kenney R.T., Spyr C.A., Lazar H., Viret J.F., Herzog C., et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 2005, 23:946.
9. Le D.T., Dubensky T.W., Brockstedt D.G. Clinical development of Listeria monocytogenes-based immunotherapies. Semin Oncol 2012, 39:311-322.
10. Jiang X., Clark R.A., Liu L., Wagers A.J., Fuhlbrigge R.C., Kupper T.S. Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity. Nature 2012, 483:227-231.
11. McLauchlin J., Low J.C. Primary cutaneous listeriosis in adults: an occupational disease of veterinarians and farmers. Vet Rec 1994, 135:615-617.
12. Whiting R, Carrington C, Hicks J, Dennis, S, Buchanan R, Brandt M, et al. quantitative assessment of relative risk to public health from foodborne Listeria monocytogenes among selected categories of ready-to-eat foods. FDA report 2003; (accessed 2012). http://www.fda.gov/downloads/food/scienceresearch/researchareas/riskassessmentsafetyassessment/ucm197330.pdf.